Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

  1. Persano, Mara
  2. Rimini, Margherita
  3. Tada, Toshifumi
  4. Suda, Goki
  5. Shimose, Shigeo
  6. Kudo, Masatoshi
  7. Rossari, Federico
  8. Yoo, Changhoon
  9. Cheon, Jaekyung
  10. Finkelmeier, Fabian
  11. Lim, Ho Yeong
  12. Presa, José
  13. Masi, Gianluca
  14. Bergamo, Francesca
  15. Amadeo, Elisabeth
  16. Vitiello, Francesco
  17. Kumada, Takashi
  18. Sakamoto, Naoya
  19. Iwamoto, Hideki
  20. Aoki, Tomoko
  21. Chon, Hong Jae
  22. Himmelsbach, Vera
  23. Iavarone, Massimo Alberto
  24. Cabibbo, Giuseppe
  25. Montes, Margarida
  26. Foschi, Francesco Giuseppe
  27. Vivaldi, Caterina
  28. Soldà, Caterina
  29. Sho, Takuya
  30. Niizeki, Takashi
  31. Nishida, Naoshi
  32. Steup, Christoph
  33. Bruccoleri, Mariangela
  34. Hirooka, Masashi
  35. Kariyama, Kazuya
  36. Tani, Joji
  37. Atsukawa, Masanori
  38. Takaguchi, Koichi
  39. Itobayashi, Ei
  40. Fukunishi, Shinya
  41. Tsuji, Kunihiko
  42. Ishikawa, Toru
  43. Tajiri, Kazuto
  44. Ochi, Hironori
  45. Yasuda, Satoshi
  46. Toyoda, Hidenori
  47. Ogawa, Chikara
  48. Nishimura, Takashi
  49. Hatanaka, Takeshi
  50. Kakizaki, Satoru
  51. Shimada, Noritomo
  52. Kawata, Kazuhito
  53. Hiraoka, Atsushi
  54. Tada, Fujimasa
  55. Ohama, Hideko
  56. Nouso, Kazuhiro
  57. Morishita, Asahiro
  58. Tsutsui, Akemi
  59. Nagano, Takuya
  60. Itokawa, Norio
  61. Okubo, Tomomi
  62. Imai, Michitaka
  63. Kosaka, Hisashi
  64. Naganuma, Atsushi
  65. Koizumi, Yohei
  66. Nakamura, Shinichiro
  67. Kaibori, Masaki
  68. Iijima, Hiroko
  69. Hiasa, Yoichi
  70. Foti, Silvia
  71. Camera, Silvia
  72. Piscaglia, Fabio
  73. Scartozzi, Mario
  74. Cascinu, Stefano
  75. Casadei-Gardini, Andrea

Download
11523_2024_Article_1061.pdf 1,35MB
WeightNameValue
1000 Titel
  • Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab
1000 Autor/in
  1. Persano, Mara |
  2. Rimini, Margherita |
  3. Tada, Toshifumi |
  4. Suda, Goki |
  5. Shimose, Shigeo |
  6. Kudo, Masatoshi |
  7. Rossari, Federico |
  8. Yoo, Changhoon |
  9. Cheon, Jaekyung |
  10. Finkelmeier, Fabian |
  11. Lim, Ho Yeong |
  12. Presa, José |
  13. Masi, Gianluca |
  14. Bergamo, Francesca |
  15. Amadeo, Elisabeth |
  16. Vitiello, Francesco |
  17. Kumada, Takashi |
  18. Sakamoto, Naoya |
  19. Iwamoto, Hideki |
  20. Aoki, Tomoko |
  21. Chon, Hong Jae |
  22. Himmelsbach, Vera |
  23. Iavarone, Massimo Alberto |
  24. Cabibbo, Giuseppe |
  25. Montes, Margarida |
  26. Foschi, Francesco Giuseppe |
  27. Vivaldi, Caterina |
  28. Soldà, Caterina |
  29. Sho, Takuya |
  30. Niizeki, Takashi |
  31. Nishida, Naoshi |
  32. Steup, Christoph |
  33. Bruccoleri, Mariangela |
  34. Hirooka, Masashi |
  35. Kariyama, Kazuya |
  36. Tani, Joji |
  37. Atsukawa, Masanori |
  38. Takaguchi, Koichi |
  39. Itobayashi, Ei |
  40. Fukunishi, Shinya |
  41. Tsuji, Kunihiko |
  42. Ishikawa, Toru |
  43. Tajiri, Kazuto |
  44. Ochi, Hironori |
  45. Yasuda, Satoshi |
  46. Toyoda, Hidenori |
  47. Ogawa, Chikara |
  48. Nishimura, Takashi |
  49. Hatanaka, Takeshi |
  50. Kakizaki, Satoru |
  51. Shimada, Noritomo |
  52. Kawata, Kazuhito |
  53. Hiraoka, Atsushi |
  54. Tada, Fujimasa |
  55. Ohama, Hideko |
  56. Nouso, Kazuhiro |
  57. Morishita, Asahiro |
  58. Tsutsui, Akemi |
  59. Nagano, Takuya |
  60. Itokawa, Norio |
  61. Okubo, Tomomi |
  62. Imai, Michitaka |
  63. Kosaka, Hisashi |
  64. Naganuma, Atsushi |
  65. Koizumi, Yohei |
  66. Nakamura, Shinichiro |
  67. Kaibori, Masaki |
  68. Iijima, Hiroko |
  69. Hiasa, Yoichi |
  70. Foti, Silvia |
  71. Camera, Silvia |
  72. Piscaglia, Fabio |
  73. Scartozzi, Mario |
  74. Cascinu, Stefano |
  75. Casadei-Gardini, Andrea |
1000 Verlag Springer International Publishing
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-04-30
1000 Erschienen in
1000 Quellenangabe
  • 19(4):645-659
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s11523-024-01061-0 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11230956/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!In the context of patients with hepatocellular carcinoma (HCC) treated with systemic therapy, the correlation between the appearance of adverse events (AEs) and reported efficacy outcomes is well-known and widely investigated. From other pathological settings, we are aware of the prognostic and predictive value of the occurrence of immune-related AEs in patients treated with immune-checkpoint inhibitors.!##!Objective!#!This retrospective multicenter real-world study aims to investigate the potential prognostic value of AEs in patients with HCC treated with atezolizumab plus bevacizumab in the first-line setting.!##!Patients and methods!#!The study population consisted of 823 patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea).!##!Results!#!Of the patients, 73.3% presented at least one AE during the study period. The most common AEs were proteinuria (29.6%), arterial hypertension (27.2%), and fatigue (26.0%). In all, 17.3% of the AEs were grade (G) 3. One death due to bleeding was reported. The multivariate analysis confirmed the appearance of decreased appetite G < 2 [versus G ≥ 2; hazard ratio (HR) 0.60; 95% confidence interval (CI) 0.13-0.90; p < 0.01] and immunotoxicity G < 2 (versus G ≥ 2; HR: 0.70; 95% CI 0.24-0.99; p = 0.04) as independent prognostic factors for overall survival, and the appearance of decreased appetite G < 2 (versus G ≥ 2; HR: 0.73; 95% CI 0.43-0.95; p = 0.01), diarrhea (yes versus no; HR: 0.57, 95% CI 0.38-0.85; p = 0.01), fatigue (yes versus no; HR: 0.82, 95% CI 0.65-0.95; p < 0.01), arterial hypertension G < 2 (versus G ≥ 2; HR: 0.68, 95% CI 0.52-0.87; p < 0.01), and proteinuria (yes versus no; HR: 0.79, 95% CI 0.64-0.98; p = 0.03) as independent prognostic factors for progression-free survival.!##!Conclusions!#!As demonstrated for other therapies, there is also a correlation between the occurrence of AEs and outcomes for patients with HCC for the combination of atezolizumab plus bevacizumab.
1000 Sacherschließung
lokal Female [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Carcinoma, Hepatocellular/pathology [MeSH]
lokal Bevacizumab/therapeutic use [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Carcinoma, Hepatocellular/drug therapy [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Liver Neoplasms/pathology [MeSH]
lokal Male [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/pharmacology [MeSH]
lokal Antibodies, Monoclonal, Humanized/therapeutic use [MeSH]
lokal Prognosis [MeSH]
lokal Bevacizumab/pharmacology [MeSH]
lokal Antibodies, Monoclonal, Humanized/pharmacology [MeSH]
lokal Original Research Article
lokal Antibodies, Monoclonal, Humanized/adverse effects [MeSH]
lokal Liver Neoplasms/drug therapy [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UGVyc2FubywgTWFyYQ==|https://frl.publisso.de/adhoc/uri/UmltaW5pLCBNYXJnaGVyaXRh|https://frl.publisso.de/adhoc/uri/VGFkYSwgVG9zaGlmdW1p|https://frl.publisso.de/adhoc/uri/U3VkYSwgR29raQ==|https://frl.publisso.de/adhoc/uri/U2hpbW9zZSwgU2hpZ2Vv|https://frl.publisso.de/adhoc/uri/S3VkbywgTWFzYXRvc2hp|https://frl.publisso.de/adhoc/uri/Um9zc2FyaSwgRmVkZXJpY28=|https://frl.publisso.de/adhoc/uri/WW9vLCBDaGFuZ2hvb24=|https://frl.publisso.de/adhoc/uri/Q2hlb24sIEphZWt5dW5n|https://frl.publisso.de/adhoc/uri/Rmlua2VsbWVpZXIsIEZhYmlhbg==|https://frl.publisso.de/adhoc/uri/TGltLCBIbyBZZW9uZw==|https://frl.publisso.de/adhoc/uri/UHJlc2EsIEpvc8Op|https://frl.publisso.de/adhoc/uri/TWFzaSwgR2lhbmx1Y2E=|https://frl.publisso.de/adhoc/uri/QmVyZ2FtbywgRnJhbmNlc2Nh|https://frl.publisso.de/adhoc/uri/QW1hZGVvLCBFbGlzYWJldGg=|https://frl.publisso.de/adhoc/uri/Vml0aWVsbG8sIEZyYW5jZXNjbw==|https://frl.publisso.de/adhoc/uri/S3VtYWRhLCBUYWthc2hp|https://frl.publisso.de/adhoc/uri/U2FrYW1vdG8sIE5hb3lh|https://frl.publisso.de/adhoc/uri/SXdhbW90bywgSGlkZWtp|https://frl.publisso.de/adhoc/uri/QW9raSwgVG9tb2tv|https://frl.publisso.de/adhoc/uri/Q2hvbiwgSG9uZyBKYWU=|https://frl.publisso.de/adhoc/uri/SGltbWVsc2JhY2gsIFZlcmE=|https://frl.publisso.de/adhoc/uri/SWF2YXJvbmUsIE1hc3NpbW8gQWxiZXJ0bw==|https://frl.publisso.de/adhoc/uri/Q2FiaWJibywgR2l1c2VwcGU=|https://frl.publisso.de/adhoc/uri/TW9udGVzLCBNYXJnYXJpZGE=|https://frl.publisso.de/adhoc/uri/Rm9zY2hpLCBGcmFuY2VzY28gR2l1c2VwcGU=|https://frl.publisso.de/adhoc/uri/Vml2YWxkaSwgQ2F0ZXJpbmE=|https://frl.publisso.de/adhoc/uri/U29sZMOgLCBDYXRlcmluYQ==|https://frl.publisso.de/adhoc/uri/U2hvLCBUYWt1eWE=|https://frl.publisso.de/adhoc/uri/TmlpemVraSwgVGFrYXNoaQ==|https://frl.publisso.de/adhoc/uri/TmlzaGlkYSwgTmFvc2hp|https://frl.publisso.de/adhoc/uri/U3RldXAsIENocmlzdG9waA==|https://frl.publisso.de/adhoc/uri/QnJ1Y2NvbGVyaSwgTWFyaWFuZ2VsYQ==|https://frl.publisso.de/adhoc/uri/SGlyb29rYSwgTWFzYXNoaQ==|https://frl.publisso.de/adhoc/uri/S2FyaXlhbWEsIEthenV5YQ==|https://frl.publisso.de/adhoc/uri/VGFuaSwgSm9qaQ==|https://frl.publisso.de/adhoc/uri/QXRzdWthd2EsIE1hc2Fub3Jp|https://frl.publisso.de/adhoc/uri/VGFrYWd1Y2hpLCBLb2ljaGk=|https://frl.publisso.de/adhoc/uri/SXRvYmF5YXNoaSwgRWk=|https://frl.publisso.de/adhoc/uri/RnVrdW5pc2hpLCBTaGlueWE=|https://frl.publisso.de/adhoc/uri/VHN1amksIEt1bmloaWtv|https://frl.publisso.de/adhoc/uri/SXNoaWthd2EsIFRvcnU=|https://frl.publisso.de/adhoc/uri/VGFqaXJpLCBLYXp1dG8=|https://frl.publisso.de/adhoc/uri/T2NoaSwgSGlyb25vcmk=|https://frl.publisso.de/adhoc/uri/WWFzdWRhLCBTYXRvc2hp|https://frl.publisso.de/adhoc/uri/VG95b2RhLCBIaWRlbm9yaQ==|https://frl.publisso.de/adhoc/uri/T2dhd2EsIENoaWthcmE=|https://frl.publisso.de/adhoc/uri/TmlzaGltdXJhLCBUYWthc2hp|https://frl.publisso.de/adhoc/uri/SGF0YW5ha2EsIFRha2VzaGk=|https://frl.publisso.de/adhoc/uri/S2FraXpha2ksIFNhdG9ydQ==|https://frl.publisso.de/adhoc/uri/U2hpbWFkYSwgTm9yaXRvbW8=|https://frl.publisso.de/adhoc/uri/S2F3YXRhLCBLYXp1aGl0bw==|https://frl.publisso.de/adhoc/uri/SGlyYW9rYSwgQXRzdXNoaQ==|https://frl.publisso.de/adhoc/uri/VGFkYSwgRnVqaW1hc2E=|https://frl.publisso.de/adhoc/uri/T2hhbWEsIEhpZGVrbw==|https://frl.publisso.de/adhoc/uri/Tm91c28sIEthenVoaXJv|https://frl.publisso.de/adhoc/uri/TW9yaXNoaXRhLCBBc2FoaXJv|https://frl.publisso.de/adhoc/uri/VHN1dHN1aSwgQWtlbWk=|https://frl.publisso.de/adhoc/uri/TmFnYW5vLCBUYWt1eWE=|https://frl.publisso.de/adhoc/uri/SXRva2F3YSwgTm9yaW8=|https://frl.publisso.de/adhoc/uri/T2t1Ym8sIFRvbW9taQ==|https://frl.publisso.de/adhoc/uri/SW1haSwgTWljaGl0YWth|https://frl.publisso.de/adhoc/uri/S29zYWthLCBIaXNhc2hp|https://frl.publisso.de/adhoc/uri/TmFnYW51bWEsIEF0c3VzaGk=|https://frl.publisso.de/adhoc/uri/S29penVtaSwgWW9oZWk=|https://frl.publisso.de/adhoc/uri/TmFrYW11cmEsIFNoaW5pY2hpcm8=|https://frl.publisso.de/adhoc/uri/S2FpYm9yaSwgTWFzYWtp|https://frl.publisso.de/adhoc/uri/SWlqaW1hLCBIaXJva28=|https://frl.publisso.de/adhoc/uri/SGlhc2EsIFlvaWNoaQ==|https://frl.publisso.de/adhoc/uri/Rm90aSwgU2lsdmlh|https://frl.publisso.de/adhoc/uri/Q2FtZXJhLCBTaWx2aWE=|https://frl.publisso.de/adhoc/uri/UGlzY2FnbGlhLCBGYWJpbw==|https://frl.publisso.de/adhoc/uri/U2NhcnRvenppLCBNYXJpbw==|https://frl.publisso.de/adhoc/uri/Q2FzY2ludSwgU3RlZmFubw==|https://frl.publisso.de/adhoc/uri/Q2FzYWRlaS1HYXJkaW5pLCBBbmRyZWE=
1000 Hinweis
  • DeepGreen-ID: 3044a3e4c3f845b59ded08db2a947e8a ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. University of Cagliari |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer University of Cagliari |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6519465.rdf
1000 Erstellt am 2025-07-05T18:04:09.035+0200
1000 Erstellt von 322
1000 beschreibt frl:6519465
1000 Zuletzt bearbeitet 2025-08-11T10:44:06.788+0200
1000 Objekt bearb. Mon Aug 11 10:44:06 CEST 2025
1000 Vgl. frl:6519465
1000 Oai Id
  1. oai:frl.publisso.de:frl:6519465 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source